一分钟看懂
这是一项关于Esophageal Squamous Cell Carcinoma的II 期研究，登记的药物或干预包括Sacituzumab tirumotecan；Toripalimab，当前状态为尚未开始招募。登记地点显示中国石家庄有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Sacituzumab tirumotecan；Toripalimab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Hebei Medical University Fourth Hospital · 石家庄
公开的入选条件
- * Age \>=18 years at the time of informed consent, either sex.
- * Histologically or cytologically confirmed locally advanced esophageal squamous cell carcinoma.
- * Judged by imaging and esophagoscopy as resectable and requiring neoadjuvant therapy, with clinical stage cT1-2N+M0 or T3-4N0-3M0 (stage II-IVA).
- * No prior antitumor therapy for esophageal squamous cell carcinoma.
- * At least one measurable lesion per RECIST v1.1.
- * ECOG performance status of 0 or 1 within 7 days before dosing.
- * Adequate organ and bone marrow function (no transfusion, recombinant human thrombopoietin, or colony-stimulating factor within 2 weeks before the first dose):
- * Hematology: NEUT# \>=1.5x10\^9/L; PLT \>=100x10\^9/L; hemoglobin \>=90 g/L.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07823270；登记信息更新于 2026-09-16。